^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Associated factors for poor response in advanced EGFR-mutated NSCLC patients under tirosine kinasa inhibitors: Peruvian real-world data
Published date:
05/19/2021
Excerpt:
...advanced NSCLC patients harboring EGFR mutations that have received TKI as first line therapy…EGFR uncommon mutations (de novo exon20 T790 mutations and exon18 G719X substitution)...odds ratio for poor response was more associated with uncommon mutations (OR = 8.21, IC95% = 1.94-97.18; p = 0.025)...According to our data, poor response is associated with uncommon EGFR mutations...
DOI:
10.1200/JCO.2021.39.15_suppl.e21214
Source:
Title:
1363P - Real-world treatment patterns of patients with locally advanced/metastatic EGFRm NSCLC in Belgium (REVEAL)
Published date:
09/14/2020
Excerpt:
In this retrospective Belgian study (REVEAL), patients diagnosed with LA/M EGFRm NSCLC...From the patients who progressed on a first 1G/2G EGFR-TKI, 72% (47/65) had a T790M test performed and 53% of them (25/47) were positive for T790M.
Trial ID:
